US · KROS
Keros Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Lexington, MA 02421
- Website
- kerostx.com
Price · as of 2024-12-31
$11.49
Market cap 575.24M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $314.53 | +2,637.42% |
| Intrinsic Value(DCF) | $9.67 | -15.84% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $65.16 | $54.20 | |||
| 2021 | $51.75 | $7.38 | $0.00 | ||
| 2022 | $44.27 | $41.05 | |||
| 2023 | $70.48 | $4.72 | $0.00 | ||
| 2024 | $11.38 | $314.53 | $8.54 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Keros Therapeutics, Inc.'s (KROS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $314.53
- Current price
- $11.49
- AI upside
- +2,637.42%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$9.67
-15.84% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| KROS | Keros Therapeutics, Inc. | $11.49 | 575.24M | +2,637% | -16% | — | — | -2.27 | 0.75 | 120.01 | 0.62 | — | 0.75 | 100.00% | -5938.96% | -5277.55% | -41.46% | -916.80% | -38.01% | 0.03 | — | 21.45 | 20.56 | 2.91 | -385.00% | 225099.00% | 2822.00% | -38.21% | -5.86 | -707.93% | 0.00% | 0.00% | 52.66% | 0.55 | 0.71 | -32.40 | 4.44 |
| ABSI | Absci Corporation | $2.74 | 412.02M | +823% | -47% | — | +302% | -3.34 | 1.92 | 75.86 | -2.57 | — | 2.56 | -1277.57% | -2401.59% | -2274.06% | -58.04% | -127.20% | -47.86% | 0.06 | -192.72 | 4.67 | 3.92 | 0.33 | -2167.00% | -2071.00% | 1116.00% | -21.17% | -2.53 | -85.05% | 0.00% | 0.00% | 0.00% | -2.22 | -3.32 | 53.29 | 1.58 |
| CRVS | Corvus Pharmaceuticals, I… | $18.26 | 1.53B | — | — | — | — | -4.52 | 8.65 | — | -8.41 | -5.57 | 8.65 | 0.00% | — | — | -174.85% | 1026.95% | -108.85% | 0.03 | — | 1.54 | 1.47 | 0.28 | 8124.00% | — | 607.00% | -9.02% | -0.72 | 947.77% | 0.00% | 0.00% | 0.00% | -8.38 | -9.08 | — | -4.40 |
| CTMX | CytomX Therapeutics, Inc. | $5.37 | 909.87M | +2,414% | -87% | -65% | +202% | 1.76 | -123.14 | 0.41 | -1.31 | — | -28.25 | 100.00% | 18.10% | 23.08% | -133.06% | -16.56% | 19.77% | -20.58 | — | 1.25 | 1.21 | -1.07 | -503506.00% | 3645.00% | 5216.00% | -154.12% | -1.01 | 57.76% | 0.00% | 0.00% | 45.36% | -1.40 | 0.41 | -0.25 | -5.71 |
| MLTX | MoonLake Immunotherapeuti… | $17.51 | 1.24B | — | — | — | — | -4.97 | 3.74 | — | -3.74 | -5.73 | 3.74 | 0.00% | — | — | -60.99% | 4029.60% | -50.78% | 0.25 | -33.78 | 9.27 | 8.77 | 1.18 | 8677.00% | — | 6740.00% | -17.20% | -4.31 | 3226.55% | 0.00% | 0.00% | 7.13% | -3.36 | -4.19 | — | 3.33 |
| NAGE | Niagen Bioscience Inc | $5.05 | 403.02M | +585% | +258% | -79% | -47% | 76.93 | 14.27 | 6.60 | 66.87 | — | 14.38 | 61.84% | 7.76% | 8.58% | 22.94% | 169.60% | 13.88% | 0.06 | — | 3.57 | 2.91 | -4.54 | -26692.00% | 1918.00% | 7142.00% | 1.82% | 0.67 | 271.59% | 0.00% | 0.00% | 2.73% | 79.72 | 51.56 | 6.18 | 16.70 |
| OLMA | Olema Pharmaceuticals, In… | $24.20 | 1.9B | — | — | — | — | -2.09 | 0.66 | — | 1.14 | -74.60 | 0.66 | 0.00% | — | — | -39.07% | 974.77% | -35.57% | 0.00 | — | 10.50 | 10.45 | 0.97 | 280.00% | — | 2482.00% | -38.59% | -2.50 | 716.12% | 0.00% | 0.00% | 26.56% | 1.14 | 1.55 | — | 2.53 |
| RGNX | REGENXBIO Inc. | $9.04 | 457.63M | +97% | -72% | — | — | -1.38 | 1.21 | 3.77 | -0.81 | — | 1.21 | 59.72% | -280.03% | -272.54% | -79.49% | -200.49% | -43.68% | 0.32 | -18.43 | 2.69 | 2.48 | -0.12 | -2375.00% | -766.00% | -2312.00% | -55.93% | -1.68 | -150.84% | 0.00% | 0.00% | 10.02% | -0.69 | -0.92 | 1.93 | -2.91 |
| RIGL | Rigel Pharmaceuticals, In… | $34.74 | 630.58M | +1,555% | +15% | -85% | +70% | 20.63 | 109.71 | 2.01 | 12.04 | — | -15.15 | 89.60% | 13.49% | 9.75% | -137.92% | -117.91% | 12.44% | 18.24 | 3.06 | 2.13 | 1.88 | 0.11 | -16875.00% | 5338.00% | -24981.00% | 8.61% | 0.50 | -159.09% | 0.00% | 0.00% | 9.58% | 14.19 | 11.05 | 1.92 | -8.42 |
| VSTM | Verastem, Inc. | $5.72 | 346.28M | — | -51% | — | — | -1.91 | -8.65 | 25.00 | -1.62 | — | -8.65 | 100.00% | -1149.56% | -1306.37% | -917.36% | 202.29% | -103.99% | -1.46 | -25.20 | 3.07 | 2.87 | 0.37 | -758.00% | — | 2121.00% | -41.92% | -3.38 | 184.42% | 0.00% | 0.00% | 4.08% | -1.77 | -1.94 | 20.34 | -14.91 |
| VTYX | Ventyx Biosciences, Inc. | $13.97 | 1B | — | — | — | — | -0.76 | 0.40 | — | 0.71 | — | 0.40 | 0.00% | — | — | -54.27% | -573.99% | -48.76% | 0.04 | — | 17.97 | 17.09 | 0.11 | -4030.00% | — | -2151.00% | -128.50% | -10.24 | -506.96% | 0.00% | 0.00% | 0.00% | 0.70 | 0.80 | — | -0.92 |
About Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
- CEO
- Jasbir S. Seehra
- Employees
- 163
- Beta
- 0.84
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($9.67 ÷ $11.49) − 1 = -15.84% (DCF, example).